跳至主要内容
临床试验/NCT02362906
NCT02362906Unknown不适用

Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by the Special Scientific Research Fund of Public Welfare Profession of China

Liaoning University of Traditional Chinese Medicine10 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2014年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
1,500
试验地点
10
主要终点
Cured rate (clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded)

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness of traditional Chinese medicine for treatment of pediatric pneumonia. It is a multicenter randomized controlled trial.

详细描述

The block randomization is used in this trial. Random numbers are generated by statistical analysis system(SAS) software. Statistical analysis staff and those who perform the follow-up are blinded. Sample size calculation was performed, which was 1164 , and considering drop-out or withdrawal, investigators plan to enroll 1500 patients (500 in experimental group 1, 500 in experimental group 2, 500 in experimental group 3).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
1 Year 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • children,aged 1 to 14 years old;
  • diagnosed as pneumonia according to western medicine diagnostic criteria;
  • diagnosed as TCM pneumonia with pneumonia with dyspnea and cough, meeting wind-heat blocking lungs pattern (feng re bi fei zheng), and phlegm-heat blocking lungs pattern(tan re bi fei zheng);
  • disease progression within 72 hours; those whose guardians understood and assigned the informed consent;

排除标准

  • severe pneumonia;
  • complicated with other Pulmonary Disorders attack other than pneumonia;
  • complicated with primary disease of heart(congenital heart disease, myocarditis, et al),liver(alanine aminotransferase(ALT),and aspartate transaminase(AST) ≥1.5 times of normal value ceiling),kidney (blood urea nitrogen(BUN) >8.2mmol/l, or serum C reactive protein >104umol/l,et al) and blood system (anemia) ,and those with psychopathy;
  • allergic to interventional medications; those who are participating or have participated in other clinical trials in 3 months;
  • those who intend to lost follow-up by practitioners' judgment.

研究组 & 干预措施

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: Xiyanping injection (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: wind-heat formula granules (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: phlegm-heat formula granules (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: Fu-xiong San (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: second generation cephalosporin (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: Erythromycin (Drug)

Injection,medications and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San.

干预措施: Azithromycin (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: Xiyanping injection (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: wind-heat formula granules (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: phlegm-heat formula granules (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: second generation cephalosporin (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: Erythromycin (Drug)

Injection and medications

Experimental

Intravenous injection:

bacterial pneumonia:second generation cephalosporin; mycoplasma pneumonia:erythromycin or azithromycin; viral pneumonia:Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules.

干预措施: Azithromycin (Drug)

Injection and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San.

干预措施: Xiyanping injection (Drug)

Injection and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San.

干预措施: Fu-xiong San (Drug)

Injection and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San.

干预措施: second generation cephalosporin (Drug)

Injection and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San.

干预措施: Erythromycin (Drug)

Injection and application

Experimental

Intravenous injection:

bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San.

干预措施: Azithromycin (Drug)

结局指标

主要结局

Cured rate (clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded)

时间窗: every day since receiving treatment,all together 7 days (times)

clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded

effective time window (days range from treatment is received to the effectiveness is observed, and symptoms disappear)

时间窗: every day since receiving treatment, all together 7 days (times)

days range from treatment is received to the effectiveness is observed, and symptoms disappear

次要结局

  • effect in treating fever(7 days)
  • effect in dyspnea releasing(7 days)
  • TCM syndrome scores(7 days)
  • effect in phlegm releasing(7 days)
  • effect in cough releasing(7 days)
  • time from admission to recovery of rales(7 days)
  • effective rate of TCM syndrome scores(7 days)
  • check-out time (days counted when the patient checks out)(7 days)
  • pulmonary disease incidence (prolonged pneumonia, chronic cough, cough variant asthma incidence in the follow-up)(15 days; 30 days; 90 days)
  • safety (With adverse events as the calculation basis)(7 days)

研究者

发起方
Liaoning University of Traditional Chinese Medicine
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xuefeng Wang

Chief physician

Liaoning University of Traditional Chinese Medicine

研究点 (10)

Loading locations...

相似试验

Effectiveness Study of Integrative Treatment for... | 临床试验